Calcitriol‐Loaded Dual‐pH‐Sensitive Micelle Counteracts Pro‐Metastasis Effect of Paclitaxel in Triple‐Negative Breast Cancer Therapy

Zheng, Zhong; Lang, Tianqun; Huang, Xin; Wang, Guanru; Lee, Robert J.; Teng, Lesheng; Yin, Qi

doi:10.1002/adhm.202000392

Cited by 25 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent preclinical study, Zheng and colleagues described a methodology to deliver paclitaxel along with calcitriol by pH-sensitive micelles, allowing for an efficient tumor uptake of the paclitaxel+calcitriol combination. This treatment suppressed primary tumor growth and inhibited lung metastasis formation in 4T1 tumor-bearing mice as a result of matrix metalloproteinase-9 (MMP)-9 and Bcl-2 level downregulation as well as E-cadherin upregulation [ 56 ]. 4T1 is an animal model for stage IV human BC.…”

Section: Calcitriol In Combination With Chemo/radiotherapy In Bcmentioning

confidence: 99%

Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update

Segovia-Mendoza

García-Quiroz

Díaz

et al. 2021

IJMS

View full text Add to dashboard Cite

Preclinical, clinical, and epidemiological studies indicate that vitamin D3 (VD) deficiency is a risk factor for the development of breast cancer. Underlying mechanisms include the ability of calcitriol to induce cell differentiation, inhibit oncogenes expression, and modify different signaling pathways involved in the control of cell proliferation. In addition, calcitriol combined with different kinds of antineoplastic drugs has been demonstrated to enhance their beneficial effects in an additive or synergistic fashion. However, a recognized adjuvant regimen based on calcitriol for treating patients with breast cancer has not yet been fully established. Accordingly, in the present work, we review and discuss the preclinical and clinical studies about the combination of calcitriol with different oncological drugs, aiming to emphasize its main therapeutic benefits and opportunities for the treatment of this pathology.

show abstract

Section: Calcitriol In Combination With Chemo/radiotherapy In Bcmentioning

confidence: 99%

Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update

Segovia-Mendoza

García-Quiroz

Díaz

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…They found that the nanoparticles promoted drug release under low pH conditions (pH 5.5), and exhibited an excellent anti-tumor effect on MCF-7 breast cancer cells in vitro. Zheng et al 16 confirmed that delivery of PTX by pH-sensitive micelles effectively inhibited primary 4T1 tumor growth in mice and inhibited metastasis to the lungs. The preparation of PTX into smart responsive micelles enhances its cytotoxicity to breast cancer cells, thereby increasing its antitumor effect.…”

Section: Introductionmentioning

confidence: 97%

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Jin¹,

Hou²,

Quan³

et al. 2021

IJN

View full text Add to dashboard Cite

Background The dual-loaded nano-delivery system can realize chemotherapeutic drug and small interfering RNA (siRNA) co-loading as well as enhance the therapeutic effect of drugs on tumors through a synergistic effect, while reducing their toxic and side effects on normal tissues. Methods Previously, we developed layered smart nanoparticles (NPs) to co-deliver survivin siRNA as well as small molecule drugs for lung cancer. In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models. For the prepared NPs, characterizations such as particle size, zeta potential, gel electrophoresis imaging and in vitro stability were investigated. Then, 4T1 cells were used to evaluate the in vitro VEGF silencing capacity, tumor cell inhibitory and anti-apoptotic abilities. Finally, an orthotopic model of mouse breast cancer was established to evaluate the in vivo antitumor effects and safety properties of PTX-siRNA VEGF -NPs. Results We prepared PTX-siRNA VEGF -NPs with particle size of 85.25 nm, PDI of 0.261, and zeta potential of 5.25 mV. The NPs with VEGF siRNA effectively knocked down the expression of VEGF mRNA. Cell counting kit-8 (CCK-8) and apoptosis assays revealed that the PTX-siRNA VEGF -NPs exhibited antiproliferation effect of PTX on 4T1 cells. The in vivo anti-tumor study indicated that PTX-siRNA VEGF -NPs could exert an antitumor effect by inhibiting the formation and development of new blood vessels in tumor tissues, thereby cutting off nutrient and blood supplies required for tumor tissue growth. Both the anti-tumor efficacy and in vivo safety of the PTX-siRNA VEGF -NPs group were better than that of the PTX-NPs and siRNA VEGF -NPs groups. Conclusion The combination of PTX and VEGF siRNA exerts good antitumor effect on 4T1 tumor cells. This study provides a theoretical and practical basis for breast cancer therapy.

show abstract

“…have been developed for targeted drug delivery. [ 41–47 ] Among potential nanocarrier forms, we synthesized a high water dispersible and biocompatible oxygen‐rich graphene oxide nanocarrier (GO‐PCH‐g‐HPG) and incorporated our selected drugs (PTX and Cur) into it. Then, we loaded the drug‐loaded GO‐PCH‐g‐HPG nanocarrier into pullulan (Pull) nanofibers using electrospinning.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of Drug‐Loaded Graphene Oxide‐Based Nanocarrier into Electrospun Pullulan Nanofibers for Potential Local Chemotherapy of Breast Cancer

Asgari

Pourjavadi

Setayeshmehr

et al. 2021

Macro Chemistry & Physics

View full text Add to dashboard Cite

With the high rate of mortality associated with breast cancer among women, breast cancer treatment has attracted great deal of attention globally. To reduce the exposure of body organs to high cytotoxicity of the common chemotherapeutic drugs, local co‐delivery of selected chemotherapeutics has emerged as a solution. In this work, an electrospun composite including a co‐drug‐loaded graphene oxide‐based nanocarrier is fabricated for local anticancer applications. To increase dispersion and cellular uptake of graphene oxide (GO), first, the hydroxyl groups at the edges of GO are grafted by poly (epichlorohydrin) (PCH) to form GO‐PCH. Then, the hydroxyl end groups of PCH are grafted (g) with hyperbranched polyglycerol (HPG) leading to formation of oxygen‐rich nanocarrier (GO‐PCH‐g‐HPG). Paclitaxel (PTX) and curcumin (Cur) are loaded into the GO‐PCH‐g‐HPG nanocarrier, and are encapsulated into pullulan nanofibers using electrospinning. SEM, FTIR, and UV–Vis characterizations confirmed the presence and distribution of the nanocarrier inside the nanofibers. The drugs showed a sustained release (93 h) from the nanocarrier‐loaded nanofibers in the neutral pH (7.4). According to MTT assay and optical microscopy, a synergistic cytotoxicity effect of PTX and Cur is observed. The nanocarrier‐encapsulated nanofiber system represents a novel tunable drug delivery system for local chemotherapeutic applications.

show abstract

Calcitriol‐Loaded Dual‐pH‐Sensitive Micelle Counteracts Pro‐Metastasis Effect of Paclitaxel in Triple‐Negative Breast Cancer Therapy

Cited by 25 publications

References 23 publications

Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update

Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

Encapsulation of Drug‐Loaded Graphene Oxide‐Based Nanocarrier into Electrospun Pullulan Nanofibers for Potential Local Chemotherapy of Breast Cancer

Contact Info

Product

Resources

About